The oncology sector has transformed over the past several decades thanks to the rise of technological advances. Through partnerships and internal innovation, LabCorp is utilising these advances in order to improve healthcare stakeholders’ experiences for better patient results.
“Across LabCorp, we innovate through science and technology, with access to approximately 2,500 [doctors] and PhDs and over 700 patients. This reach allows us to support 82% of the novel drugs and therapeutic products approved by the US FDA, including 63% of those specific to oncology,” Reddy states.
